Around 5 drugs have either been approved by the government to use or are in the final stages of clinical trials.
With the scaring rise in COVID-19 cases every day, India is all in to find a solution to teat the deadly novel virus. Several states in India are reporting a new high in the number of COVID-19 cases.
Currently, the government of India has approved around 5 drugs for either a go-ahead or for clinical trials. Three of these medicines have already been approved by the DGCI while the other two are in the final stages of a trial.
Recently India recorded the third-highest single day hike taking it up the third place in the ladder of the highest number of COVID-19 cases, trailing behind USA and Brazil.
The 5 drugs include:
Tocilizumab: An immunosuppressive drug known to treat arthritis. Usually, in the form of a monoclonal antibody, the drug is being tried on severe COVID-19 patients.
Itolizumb: A first-class humanized IgG1 monoclonal antibody, the drug selectively targets CD6 and helps in maturing T cells. Currently, the drug is being used in both Mumbai and Delhi.
Cipremi: A remedesivir, the medicine is a lyophilized powder marketed by both government and market channels. Currently, the drug has been approved for the use in adults and pediatric patients.
FabiFlu: Global trails have shown that this cost-effective drug has efficacy of 80-88%. Currently Japan, UAE and Bangladesh are already using teh drug. The drugs are available through both hospital and retail channels.
Covifor: An injectable drug, is currently being used in hospitals under the supervision of healthcare clinicians.
To know more about origin, virology of COVID-19, Click here
To know more about emerging themes in COVID-19, Click here
To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com
Want to set up an online consultation for your practice, Click here